文献速递甲状腺疾病

甲状腺细针穿刺中许特莱细胞的存在并未增加大多数Bethesda分类的恶性风险

The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
PubMed 文献 · Thyroid · 2020-01-01

该回顾性研究纳入2000至2013年间300例甲状腺细针穿刺显示许特莱细胞/嗜酸细胞改变且最终有手术病理的患者,并与多机构FNA队列比较。总体上许特莱细胞的存在与各Bethesda分类恶性风险降低相关,但在Bethesda II类中当许特莱细胞为主(>75%)时恶性率显著升高。

要点

  • 许特莱细胞存在时,BSRTC IV和V类的恶性风险显著低于多机构FNA队列。
  • 除Bethesda II类外,许特莱细胞存在不增加各BSRTC分类的恶性风险。
  • 当许特莱细胞为主(>75%)时,Bethesda II类(良性细胞学)的恶性率显著升高。

核心结论

  • 尽管临床医生将许特莱细胞视为「非典型细胞」,但其存在总体上不增加BSRTC分类内的恶性风险。
  • 然而,当许特莱细胞改变为主时,良性细胞学/BSRTC II类的恶性风险增加。

研究设计与样本

  • 回顾性审查2000至2013年间一家三级转诊中心300例FNA显示许特莱细胞/嗜酸细胞改变且有最终手术病理的患者记录,并与多机构FNA队列比较。

主要发现

  • 许特莱细胞FNA组BSRTC分类:I类(无法诊断)14例(4.7%);II类(良性)113例(37.7%);III类(意义不明的非典型性/意义不明的滤泡性病变)33例(11%);IV类(滤泡性肿瘤/可疑滤泡性肿瘤)125例(41.6%);V类(可疑恶性)12例(4%);VI类(恶性)3例(1%)。
  • 按许特莱细胞改变程度分类:轻度59例(29%),中度13例(6%),为主131例(65%)。
  • 与多机构FNA队列(均有手术确认)比较,许特莱细胞的存在与所有BSRTC分类中恶性风险降低相关,在BSRTC IV和V组差异有统计学意义。
  • 唯一例外是当许特莱细胞存在被归类为主(定义为占细胞群体>75%)时,在判读为良性/Bethesda II的FNA中恶性率显著升高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Hürthle cell/oncocytic change is commonly reported on thyroid fine-needle aspiration (FNA) and may be considered an "atypical cell" by clinicians. This study aims to delineate the association between Hürthle cells in preoperative cytology and subsequent pathology of the indexed thyroid nodule and to report rates of malignancy. Methods: Retrospective review of records of 300 patients with Hürthle cell/oncocytic change on FNA and final surgical pathology at a tertiary referral center between 2000 and 2013 was performed and compared with a multi-institutional FNA cohort. The degree of Hürthle cell presence was correlated with histopathologic diagnoses. Results: In the Hürthle cell FNA group, Bethesda System for Reporting Thyroid Cytopathology (BSRTC) categories were as follows: I (nondiagnostic) 14 (4.7%); II (benign) 113 (37.7%); III (atypia of undetermined significance/follicular lesion of undetermined significance) 33 (11%); IV (follicular neoplasm/suspicious for a follicular neoplasm) 125 (41.6%); V (suspicious for malignancy) 12 (4%); and VI (malignant) 3 (1%). When categorized based on the degree of Hürthle cell change, 59 (29%) were classified as mild, 13 (6%) moderate, and 131 (65%) as predominant. When comparing the results with a multi-institutional FNA cohort (all with surgical confirmation), the presence of Hürthle cells was found to be associated with a lower risk of malignancy in all BSRTC categories, with a statistically significant difference in the BSRTC IV and V groups. The sole exception was when Hürthle cell presence was classified as predominant (defined as >75% of the cellular population); the rate of malignancy was significantly elevated in FNAs interpreted as benign/Bethesda II. Conclusions: Although Hürthle cells have been considered by clinicians as an "atypical cell," their presence does not increase the risk of malignancy within BSRTC categories overall. However, when predominant Hürthle cell change is present, the risk of malignancy is increased in the benign cytology/BSRTC category II.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ren Y, Kyriazidis N, Faquin WC, et al. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates. Thyroid. 2020. PMID: 32013786. doi:10.1089/thy.2019.0190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。